Literature DB >> 12716776

Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus.

Elias K Manavathu1, George J Alangaden, Pranatharthi H Chandrasekar.   

Abstract

OBJECTIVES: We investigated the in vitro activity of various triazoles in two-drug combinations with the echinocandin caspofungin against clinical isolates of Aspergillus fumigatus.
METHOD: Conidial suspensions were prepared from 20 clinical isolates of A. fumigatus highly susceptible to itraconazole, voriconazole, posaconazole and ravuconazole (MIC-0 range 0.125-1 mg/L), and caspofungin (MIC-0 range 32-64 mg/L). The in vitro susceptibility of A. fumigatus to two-drug combinations of itraconazole, voriconazole, posaconazole and ravuconazole with caspofungin was evaluated by the fractional inhibitory concentration index (FICI) method.
RESULTS: Two-drug combinations of caspofungin with itraconazole (FICI = 0.49 +/- 0.04) or posaconazole (FICI = 0.32 +/- 0.09) provided synergic interaction. On the other hand, ravuconazole (FICI = 0.61 +/- 0.31) and voriconazole (FICI = 1.61 +/- 0.42) in combination with caspofungin showed no interaction against A. fumigatus.
CONCLUSIONS: Our data show that the in vitro antifungal efficacies of combinations of members from two different classes are not always similar and hence are not predictable.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12716776     DOI: 10.1093/jac/dkg242

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  24 in total

Review 1.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Differences in interactions between azole drugs related to modifications in the 14-alpha sterol demethylase gene (cyp51A) of Aspergillus fumigatus.

Authors:  G Garcia-Effron; E Mellado; A Gomez-Lopez; L Alcazar-Fuoli; M Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

4.  Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

Authors:  Donna M MacCallum; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.

Authors:  Anthony Cacciapuoti; Judith Halpern; Cara Mendrick; Christine Norris; Reena Patel; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 6.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

7.  The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.

Authors:  Eleftheria Mavridou; Joseph Meletiadis; Antony Rijs; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

8.  Use of Antifungal Combination Therapy: Agents, Order, and Timing.

Authors:  Melissa D Johnson; John R Perfect
Journal:  Curr Fungal Infect Rep       Date:  2010-05-01

Review 9.  [Therapy of severe fungal infections].

Authors:  M Battegay; U Flückiger
Journal:  Internist (Berl)       Date:  2003-12       Impact factor: 0.743

10.  Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp.

Authors:  Joanne P Demchok; Joseph Meletiadis; Emmanuel Roilides; Thomas J Walsh
Journal:  Mycoses       Date:  2009-03-07       Impact factor: 4.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.